SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02960607

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase II Study of High-dose Icotinib in Previously Treated Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutation

The purpose of this study is to investigate whether high-dose icotinib treatment beyond disease progression is beneficial for NSCLC patients who have EGFR mutation and who have responded to EGFR TKI.

NCT02960607 Carcinoma, Non-Small-Cell Lung
MeSH:Carcinoma, Non-Small-Cell Lung
HPO:Non-small cell lung carcinoma

1 Interventions

Name: Icotinib

Description: Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
Type: Drug
Group Labels: 1

Icotinib


Primary Outcomes

Measure: Progression Free survival

Time: 2 years

Purpose: Treatment

Allocation: N/A

Single Group Assignment


There is one SNP

SNPs


1 T790M

Inclusion Criteria: - Histologically confirmed stage IIIB/IV NSCLC - Investigator confirmed progression according RECIST 1.1 during previous icotinib treatment - Patients whose tumors: - are EGFR mutation-positive or - T790M mutation-negative - Performance status: WHO 0-2 - Measurable disease according to RECIST 1.1 - at least one measureable lesion .if --- T790M ---

- Patient with uncontrolled undercurrent illness or circumstances that could limit compliance with the study Inclusion Criteria: - Histologically confirmed stage IIIB/IV NSCLC - Investigator confirmed progression according RECIST 1.1 during previous icotinib treatment - Patients whose tumors: - are EGFR mutation-positive or - T790M mutation-negative - Performance status: WHO 0-2 - Measurable disease according to RECIST 1.1 - at least one measureable lesion .if --- T790M ---



HPO Nodes


HPO: